Firehawk® Obtains Registration Approval in Egypt

Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) received registration approval for its self-developed Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk®”) from the Central Administration for Pharmaceutical Affairs (CAPA) of Egypt on November 3, 2019, which is the first registration approval granted for the Firehawk® in Africa.

Firehawk® obtained the CE mark in 2015 and has been approved for marketing in more than 20 Asian and Latin American countries such as India, South Korea, Brazil and Argentina. The approval for Firehawk® in Egypt marks a new breakthrough of MicroPort® in the overseas market. Firehawk® is expected to take advantage of its outstanding superiority in performance to provide patients in Africa with even better cardiovascular therapeutic solutions.
MicroPort® Access Receives NMPA Registration Certificate for Guiding Catheter

MicroPort® Access Medtech (Jiaxing) Co., Ltd (MicroPort® Access Jiaxing), a subsidiary of Shanghai MicroPort® Access Medtech Co., Ltd. (MicroPort® Access), received the registration certificate for its self-developed guiding catheter from National Medical Products Administration of China (NMPA) on November 1, 2019.

Guiding catheter, which is one of the key contributors to successful percutaneous coronary intervention (PCI) therapy, is mainly used to provide route for the introduction of PCI devices. The approved guiding catheter features excellent torque control performance to facilitate operators’ easy control of catheter to the planned vessel. The large lumen and thin-walled body of the catheter give operators more operational room, with appropriate back-up support for the distal end provided at the same time. The distal flexural high-contrast radiopaque segment and the soft tip can provide clearer visibility and further lower probability of endothelia damage at the same time.

The approval for the guiding catheter further improves MicroPort® product line of PCI. In the future, MicroPort® Access will continue the R&D of high-performance devices to provide more comprehensive PCI solutions for patients and doctors.
MicroPort® MedBot’s Toumai™ Endoscopic Surgical System Completes First-ever Case of Robotic-Assisted Laparoscopic Radical Prostatectomy (RALRP) in Clinical Study

The Toumai™ Endoscopic Surgical System ("Toumai™") produced by MicroPort® MedBot (Shanghai) Co., Ltd. ("MicroPort® MedBot"), which is a subsidiary of MicroPort® and specialized in robotics, completed its first-ever case of Robotic-Assisted Laparoscopic Radical Prostatectomy (RALRP) at the East Hospital in Shanghai, China, on November 1, 2019. With the assistance provided by Toumai™, a team led by Academician Yinhao Sun, who is from the Urology Department of Shanghai Hospital of Shanghai, successfully performed the RALRP on a 65-year-old male patient.

The case marked the first-ever RALRP performed by a Chinese-made endoscopic robotic system, with Toumai™ becoming China’s first endoscopic robotic system to perform the challenging urological procedure. The case also signified that Chinese-made endoscopic robotic system is able to perform the challenging and complex procedure such as RALRP.

The Toumai™ has achieved independent innovation with regards to the underlying technologies of main body of the robotic system, the 3D electronic laparoscope, and the robotic control algorithm, which has solved a series of bottleneck issues during the course of commercialization. Compared to similar imported system, Toumai™ optimizes operator’s experience, reduces the costs of system maintenance and supply materials, and is expected to blaze a trail for the campaign of “Made in China Intelligently” in the area of surgical robotics.
MicroPort® Orthopedics Attends COA 2019

Suzhou MicroPort Orthopedics Scientific (Group) Co., Ltd. (“MicroPort® Orthopedics”) recently attended the 14th Annual Congress of Chinese Orthopaedic Association (COA 2019), which was held by Chinese Medical Association and Chinese Orthopaedic Association at the National Exhibition and Convention Center (Shanghai). As the biggest international scientific event in the Chinese or even the world’s orthopedics community, the COA 2019, which covered the various fields including clinical orthopedics, rehabilitation, nursing and basics, displayed the latest research results, latest techniques and clinical progresses that had been achieved in the orthopedic field. MicroPort® Orthopedics exhibited the innovative devices in the various disciplines of joint, spine, trauma, orthopedic instruments and rehabilitation to demonstrate its multi-dimensional and integrated therapeutic solitons to orthopedic diseases.

During the congress, MicroPort® Orthopedics also displayed the first Medial-Stabilized Total Knee Replacement System that was approved in China with independent intellectual property - Aspiration™ and SoSuperior™ Medial-Stabilized Total Knee Replacement implants, as well as series of innovative devices in the spine and trauma segments, including ARBORES® Vertebroplasty Dilation Balloon Catheter, Piscis®-II Cage, Spinal multifunctional fixation system, New intramedullary nails suitable for human bones - Trailwalker™ PFNA, Tibial interlocking intramedullary nail system, Femoral interlocking intramedullary nail system. All the devices attracted groups of healthcare professionals to have visits and exchanges. They also visited the classroom for surgical instrument demonstrations in the Renshou Hall Education and Training Center, which MicroPort® Orthopedics inaugurated in 2019, and gained deep insights into the new knee instruments self-developed by MicroPort® Orthopedics. The instrument set has undergone technological innovation and design improvements on the basis of Chinese doctors’ clinical experience to become more in line with their surgical routines. In addition, the instrument set provides more options for positioning angles to increase the smoothness and flexibility of the procedure, shorten operation time, and reduce the rate of postoperative complications, which reflects the international standard of the concept of Made in China with “Intelligence”.
MicroPort® NeuroTech Attends 2nd Shaolin Interventional Neurosurgical Conference and 5th Central China Cerebrovascular Disease Forum

MicroPort NeuroTech (Shanghai) Co., Ltd. (“MicroPort® NeuroTech”) attended the 2nd Shaolin Interventional Neurosurgical Conference and 5th Central China Cerebrovascular Disease Forum (SINC & CCDF) which was held from November 8 to 10 and brought together domestic and foreign healthcare professionals in the areas of neurosurgery and cerebrovascular diseases to discuss scientific topics and improve surgical skills. MicroPort® NeuroTech presented at SINC & CCDF Tubridge® Vascular Reconstruction Device (“Tubridge®”) and other innovative devices. The attending healthcare professionals were deeply impressed with the company’s integrated neurovascular interventional solutions.

During the “Forum for Aneurysms, Brain AVM, and Cerebrosinal and Vascular Disease Combined Procedure”, Professor Li Li from Henan Provincial People’s Hospital gave a speech titled “The Single Center Experience and Edited Case of Tubridge®”. Professor Li Li presented a comprehensive review of the application experience of Tubridge® in combination with the cases performed at the hospital, which was followed by edited cases to deepen the audience’s understandings of the mesh stent’s key application essentials. Professor Xiaodong Xie from West China Hospital of Sichuan University spoke under the title of “Clinical Application of WILLIS® Intracranial Stent Graft System”. He used his own rich clinical experience to discuss the application of WILLIS® Intracranial Stent Graft System in the treatment of aneurysms from the perspective of indications.

Tubridge® is an innovative device for the treatment of big and huge intracranial aneurysms, which resulted from 12 years of independent development. The device is also the first Chinese-made blood flow diverting device approved to launch in China. Since its launch in 2018, the device has received positive clinical feedbacks and endorsement from healthcare professionals. MicroPort® NeuroTech President Mr. Yongzhi Xie said: “MicroPort® NeuroTech will continue to listen intently to feedbacks from clinicians and continuously optimize the technologies and processes for our devices to provide doctors and patients with more neurovascular interventional solutions of higher quality.”
Firehawk® Project
Wins 2019 PMI (China) Project Management Award – Excellent Project

On October 26-27, 2019, the project of Firehawk® won the 2019 PMI (China) Project Management Award – Excellent Project during the PMI (China) 2019 Project Management Congress held by Project Management Institute (PMI) at the Shanghai International Convention Center. Firehawk® is produced by MicroPort®.

Previously, the MicroPort® Project Management Team won the PMI (China) Project Management Award – Annual PMO Award in 2016. MicroPort® is the first Chinese medical device corporation to win the PMI awards since the establishment of PMI in 1969 and the introduction of PMP (Project Management Professional) certification into Chinese mainland in 1999. The second PMI award for MicroPort®, which was thanks to the Firehawk® project, fully demonstrated that the project management level and practice experience of MicroPort® had been highly recognized by industry experts. In the future, MicroPort® will continue to adhere to the R&D philosophy of unrelenting innovation to continuously accumulate practice experience in project management. MicroPort® will optimize its management mode and methods and promote the development of innovative products to provide doctors and patients with integrated therapeutic solutions of higher quality and more precision.
For more information, please contact:

**Martin Sun**  
Chief Financial Officer  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com

**Leanne Li**  
Board Secretary & Vice President  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com